Acute myelogenous leukemia in the elderly (>or=60): retrospective study of 115 patients / 대한내과학회지
Korean Journal of Medicine
; : 196-206, 2006.
Article
in Ko
| WPRIM
| ID: wpr-190597
Responsible library:
WPRO
ABSTRACT
BACKGROUND: Acute myelogenous leukemia (AML) is frequently encountered in elderly patients whereas intensive chemotherapy yield lower rate of complete remission (CR) and survival than young patients. This study was aimed to review the clinical features and treatment outcomes of elderly patients (>or=60) with AML. METHODS: We respectively reviewed the clinical features, laboratory findings and outcomes of treatment from the medical records of 115 patients with the elderly AML (>or=60), admitted in Seoul National University Hospital, between Jan.1995 and Dec.2004. RESULTS: Their median age was 66 (60~86) years with male predominance (M:F=68:47). Complete response rate in patients with conventional chemotherapy was 66.7% (42 of 63 patients; 95% CI 50.2~78.4). Median overall survival (OS) was 5.2 months with clinical benefit in the conventional chemotherapy group, compared to supportive or palliative group (11.5 vs 0.9months; p<0.0001). In between two age groups, the sixties (n=69) showed higher CR rate (69.0 vs 61.9%; p=0.9) and longer median overall survival (7.0 vs 4.4months; p=0.8) than patients group of the seventies (n=38) but without statistical significance. CONCLUSIONS: Conventional induction chemotherapy improved survival rate than palliative or supportive treatment.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Prognosis
/
Leukemia, Myeloid, Acute
/
Medical Records
/
Survival Rate
/
Retrospective Studies
/
Drug Therapy
/
Induction Chemotherapy
/
Seoul
Type of study:
Observational_studies
/
Prognostic_studies
Limits:
Aged
/
Humans
/
Male
Country/Region as subject:
Asia
Language:
Ko
Journal:
Korean Journal of Medicine
Year:
2006
Document type:
Article